SMIC Allegedly Supplies Chipmaking Tools to Iran's Military, U.S. Officials Warn 
SK Hynix Eyes Up to $14 Billion U.S. IPO to Fund AI Chip Expansion 
Lynas Rare Earths Signs Vietnam Deal with LS Eco Energy to Boost Magnet Metal Production 
Brazil Meat Exports Weather Iran War Disruptions With Rerouted Shipments 
SpaceX IPO Filing Expected This Week as Valuation Could Surpass $75 Billion 
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs 
Nanya Technology Shares Surge 10% After $2.5 Billion Private Placement from Sandisk and Cisco 
Unilever and Magnum Face Defamation Lawsuit Over Ben & Jerry's Board Chair Dismissal 
Innate Pharma Reports 55% Revenue Drop and €49.2M Net Loss for 2025 
NAB Plans to Cut 170 Jobs While Expanding Offshore Operations 
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand 
Meta Ties Executive Pay to Aggressive Stock Price Targets in Major Retention Push 
Brown-Forman and Pernod Ricard in Merger Talks to Create World's Largest Spirits Giant 
Valero Port Arthur Refinery Explosion Prompts $1M Lawsuit Over Worker Safety Negligence 
Bank of America's $72.5M Epstein Settlement: What You Need to Know 
Federal Judge Blocks Pentagon's Blacklisting of AI Company Anthropic 
Reflection AI Eyes $25 Billion Valuation in Massive $2.5 Billion Funding Round 
SAN RAMON, Calif., Jan. 11, 2016 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company committed to the development and commercialization of targeted oncology therapeutics that address major unmet medical needs, today announced that Mark W. Schwartz, Ph.D., President and Chief Executive Officer will present a corporate update at NobleCon12 - Noble Financial Capital Markets’ Twelfth Annual Investor Conference. The presentation will take place on Monday, January 18, 2015 at 2:30 p.m. ET in Sandpiper Bay, Florida.
The presentation will be webcast and available on the Investors section of the Company's website at http://investors.galenabiopharma.com/events.cfm.
About Galena Biopharma
Galena Biopharma, Inc. is a biopharmaceutical company committed to the development and commercialization of targeted oncology therapeutics that address major unmet medical needs. Galena’s development portfolio is focused primarily on addressing the rapidly growing patient populations of cancer survivors by harnessing the power of the immune system to prevent cancer recurrence. The Company’s pipeline consists of multiple mid- to late-stage clinical assets, including novel cancer immunotherapy programs led by NeuVax™ (nelipepimut-S) and GALE-301. NeuVax is currently in a pivotal, Phase 3 clinical trial with several concurrent Phase 2 trials ongoing both as a single agent and in combination with other therapies. GALE-301 is in a Phase 2a clinical trial in ovarian and endometrial cancer and in a Phase 1b given sequentially with GALE-302. For more information, visit www.galenabiopharma.com.
NeuVax is a trademark of Galena Biopharma, Inc.
Contact:
Remy Bernarda
SVP, Investor Relations & Corporate Communications
(925) 498-7709
[email protected]
